Detection of Early Idiopathic Pulmonary Fibrosis

N/AActive Not RecruitingNCT03457935

Temple University450 enrolled

Overview

The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.

Study Type

OBSERVATIONAL

Enrollment

450

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

blood samplesOTHER

Blood samples

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria for IPF Patients: * Informed consent * Subjects ≥ 40 y.o. * Naive patients with no IPF treatment * IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria Inclusion Criteria for non-IPF ILD Patients: * Informed consent * Subjects ≥ 18 y.o. * ILD diagnosis Exclusion Criteria: * HIV * Hepatitis B * Hepatitis C * Pregnant or lactating women inclusion criteria for controls: informed consent \>18 years old; no lung diseases

Locations (1)

Temple University

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

To determine miR200 levels (fold change) in blood samples.

MicroRNAs (miRs) are noncoding small RNAs, which regulate numerous physiological and pathological processes. miR200 levels will be measured in blood samples collected from control subjects, non-IPF ILD and IPF patients. These samples will be used for identifying biomarkers for IPF.

Time frame: Baseline (one time).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.